ライフサイエンスコーパス: orthotopic liver transplantation

1 of the PDCD1 SNP PD1.3 were associated with orthotopic liver transplantation.

2 including their management during and after orthotopic liver transplantation.

3 t both of bone marrow transplantation and of orthotopic liver transplantation.

4 ermia appears to be promising as a bridge to orthotopic liver transplantation.

5 manipulations, ammonia scavenger drugs, and orthotopic liver transplantation.

6 nctional rate observed in marginal steatotic orthotopic liver transplantation.

7 potentially fatal complication of piggyback orthotopic liver transplantation.

8 c venous outflow obstruction after piggyback orthotopic liver transplantation.

9 y section, especially in a center performing orthotopic liver transplantation.

10 perfusion injury still impact the outcome of orthotopic liver transplantation.

11 with outcome in HCV- and HCV+ recipients of orthotopic liver transplantation.

12 ogic CR; one HCC patient with a PR underwent orthotopic liver transplantation.

13 ed fatty Zucker rat model of I/R followed by orthotopic liver transplantation.

14 ter experience in the care of children after orthotopic liver transplantation.

15 fy factors that predict HCC recurrence after orthotopic liver transplantation.

16 r advanced liver disease, underwent isolated orthotopic liver transplantation.

17 cyclopropenone while on the waiting list for orthotopic liver transplantation.

18 ronic graft-versus-host disease (GVHD) after orthotopic liver transplantation.

19 stent removal was deferred until the time of orthotopic liver transplantation.

20 or VII deficiency, successfully treated with orthotopic liver transplantation.

21 ctomy has not been previously reported after orthotopic liver transplantation.

22 es the number of deaths in patients awaiting orthotopic liver transplantation.

23 treatment by portal decompression, required orthotopic liver transplantation.

24 s are refractory to drug therapy and require orthotopic liver transplantation.

25 ed) recipient rats on days 2, 4, and 7 after orthotopic liver transplantation.

26 r other hepatic arterial complications after orthotopic liver transplantation.

27 ificantly different from that of whole-organ orthotopic liver transplantation.

28 ssion, and they were approved and listed for orthotopic liver transplantation.

29 n of serum tacrolimus level after successful orthotopic liver transplantation.

30 munodeficiency virus infection who underwent orthotopic liver transplantation.

31 Three patients have undergone orthotopic liver transplantation.

32 % of the pediatric population that undergoes orthotopic liver transplantation.

33 s performed in 25 patients who had undergone orthotopic liver transplantation.

34 ase in children and may lead to the need for orthotopic liver transplantation.

35 er tissue for HGV-RNA in patients undergoing orthotopic liver transplantation.

36 lant day 16, the animals underwent syngeneic orthotopic liver transplantation.

37 ve children with monoclonal LPD complicating orthotopic liver transplantation.

38 s found in the portal vein at the time of an orthotopic liver transplantation.

39 y rats were used as donors and recipients of orthotopic liver transplantation.

40 tumors) is limited to surgical resection or orthotopic liver transplantation.

41 rolled, followed by 3 h of SNMP recovery and orthotopic liver transplantation.

42 rmothermic machine perfusion (NMP) and after orthotopic liver transplantation.

43 ement of BM-HSCs in liver regeneration after orthotopic liver transplantation.

44 N-based treatment response in patients after orthotopic liver transplantation.

45 idence is needed to fully define the role of orthotopic liver transplantation.

46 eased risk for morbidity and mortality after orthotopic liver transplantation.

47 ard approaches to in situ anastomosis during orthotopic liver transplantation.

48 nced hepatic encephalopathy who are awaiting orthotopic liver transplantation.

49 that seen after isolated orthotopic heart or orthotopic liver transplantation.

50 llion people and is the major indication for orthotopic liver transplantations.

51 Forty-eight and 52 months after orthotopic liver transplantation, all surviving patients

52 ients who underwent chemoembolization before orthotopic liver transplantation and those who did not.

53 (HCC) recurrence and overall survival after orthotopic liver transplantation and to identify factors

54 patient spontaneously recovered, 1 required orthotopic liver transplantation, and 1 died.

55 were as follows: 28% recovered, 52% required orthotopic liver transplantation, and 20% died.

56 ts infected with hepatitis C virus following orthotopic liver transplantation, and investigation cont

57 Even though auxiliary partial orthotopic liver transplantation (APOLT) as a technique

58 association between BMI and waiting time for orthotopic liver transplantation as a surrogate marker f

59 severe multisystem manifestations underwent orthotopic liver transplantation at age 50 months for th

60 A patient on waitlist for orthotopic liver transplantation because of decompensate

61 sity of Rochester Medical Center (URMC) with orthotopic liver transplantation between 1998-2008.

62 with results in 1,154 patients who underwent orthotopic liver transplantation but not chemoembolizati

63 Of the 1,154 patients who underwent orthotopic liver transplantation but not chemotherapy, 6

64 ty using the original equation suggests that orthotopic liver transplantation, by reversing the under

65 rative cardiovascular risk stratification in orthotopic liver transplantation candidates has proven c

66 A prospective cohort study of 7906 orthotopic liver transplantations carried out between Ap

67 fication caused by chronic renal failure and orthotopic liver transplantation, dystrophic calcificati

68 ne green uptake, arterial ketone body ratio, orthotopic liver transplantation) experiments were condu

69 ase, we identified 54 patients who underwent orthotopic liver transplantation for cryptogenic cirrhos

70 Nine patients receiving orthotopic liver transplantation for end-stage HCV-relat

71 ntation for patients with primary (AL) or by orthotopic liver transplantation for familial (ATTR) amy

72 Orthotopic liver transplantation for HBV under combinati

73 Orthotopic liver transplantation for HCV is performed wi

74 on (RT in situ RCR) in hepatic tissue, after orthotopic liver transplantation for HCV-related liver d

75 Hepatitis C infection recurs after orthotopic liver transplantation for hepatitis C virus (

76 s operation, making it a safe alternative to orthotopic liver transplantation for patients with a wid

77 juvant radiotherapy, chemosensitization, and orthotopic liver transplantation for patients with opera

78 ur institution, nine patients have undergone orthotopic liver transplantation for symptomatic hepatic

79 The role of orthotopic liver transplantation for the treatment of be

80 esent the first series of patients receiving orthotopic liver transplantation for this condition.

81 tation, which is a less invasive method than orthotopic liver transplantation for treatment of metabo

82 vanced liver disease should be evaluated for orthotopic liver transplantation from a cadaver donor or

83 identification of a complicated course after orthotopic liver transplantation from deceased donors ar

84 18 measurements in routine diagnostics after orthotopic liver transplantation from deceased donors sh

85 hort-term complications within 10 days after orthotopic liver transplantation from deceased donors.

86 s and inflammatory markers in patients after orthotopic liver transplantation from deceased donors.

87 th male donors and from 4 male recipients of orthotopic liver transplantations from female donors.

88 dly in transplanted kidneys, and concomitant orthotopic liver transplantation has lately been perform

89 r failure from alcoholic cirrhosis underwent orthotopic liver transplantation; however, an intraopera

90 t animal models of hepatic warm ischemia and orthotopic liver transplantation (hypothermic ischemia).

91 lop rejection within the first 30 days after orthotopic liver transplantation if the patient did not

92 ent was by liver resection in 6 patients and orthotopic liver transplantation in 2.

93 ve repair can be performed safely along with orthotopic liver transplantation in carefully selected p

94 study was designed to analyze the outcome of orthotopic liver transplantation in compromised rat host

95 During orthotopic liver transplantation in humans, we observed

96 in of hepatocytes in sex-mismatched cases of orthotopic liver transplantation in longitudinally perfo

97 tients, steroid therapy in two patients, and orthotopic liver transplantation in one patient.

98 There is concern that repeat orthotopic liver transplantation in patients with hepati

99 Orthotopic liver transplantation in the mouse is a power

100 Despite the efficacy of orthotopic liver transplantation in the treatment of end

101 Kingdom (P=0.37, log-rank test) and isolated orthotopic liver transplantation in the United States (P

102 Orthotopic liver transplantation in the United States is

103 plasty procedure was used in 115 consecutive orthotopic liver transplantations, including six left la

104 aled NO (iNO; 80 ppm) to patients undergoing orthotopic liver transplantation inhibits hepatic IR inj

105 The piggyback technique of orthotopic liver transplantation is an attractive altern

106 N or FK and an identical steroid taper after orthotopic liver transplantation is associated with exce

107 Late graft dysfunction after orthotopic liver transplantation is commonly due to chro

108 Orthotopic liver transplantation is currently the only c

109 Orthotopic liver transplantation is effective and potent

110 th chronic hepatitis C virus infection after orthotopic liver transplantation is excellent, significa

111 nce that mTORi prevents HCC recurrence after orthotopic liver transplantation is only suggestive.

112 Orthotopic liver transplantation is possible even in the

113 Orthotopic liver transplantation is the only available t

114 Orthotopic liver transplantation is the only definitive

115 cirrhosis from long-standing, untreated BCS, orthotopic liver transplantation is the only hope of rel

116 Orthotopic liver transplantation is the only proven effe

117 Orthotopic liver transplantation is the treatment of cho

118 entified as a potential contraindication for orthotopic liver transplantation (LT) because of lower s

119 Nine proceeded to orthotopic liver transplantation (mean 74 days to transp

120 umented by means of pathologic inspection at orthotopic liver transplantation (median shunt duration,

121 After orthotopic liver transplantation, metformin precondition

122 Orthotopic liver transplantation might be applicable for

123 Setup of the orthotopic liver transplantation model comprises three m

124 Here we test this hypothesis in an optimized orthotopic liver transplantation model.

125 in IRI to liver grafts using a syngeneic rat orthotopic liver transplantation model.

126 uction and maintenance of tolerance in a rat orthotopic liver transplantation model.

127 She had undergone orthotopic liver transplantation (OLT) 15 months before

128 ilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant

129 in rat liver models of ex vivo perfusion and orthotopic liver transplantation (OLT) after prolonged p

130 itochondrial antibody (AMA) status and prior orthotopic liver transplantation (OLT) among the PBC pat

131 Fourteen patients with ALF who were awaiting orthotopic liver transplantation (OLT) and had increased

132 lic disorders are common complications after orthotopic liver transplantation (OLT) and may lead to i

133 inferior outcomes compared with the primary orthotopic liver transplantation (OLT) and raises concer

134 cal decision-making and organ allocation for orthotopic liver transplantation (OLT) and was previousl

135 an Americans compared with other races after orthotopic liver transplantation (OLT) and whether race

136 nts who underwent evaluation, treatment, and orthotopic liver transplantation (OLT) at their institut

137 to preserve renal function in patients after orthotopic liver transplantation (OLT) based on estimate

138 Patients receiving orthotopic liver transplantation (OLT) because of type D

139 c) provide effective immunosuppression after orthotopic liver transplantation (OLT) but can cause ren

140 mining of intraoperative hemodynamic data in orthotopic liver transplantation (OLT) can aid in the pr

141 Orthotopic liver transplantation (OLT) can be a definiti

142 Orthotopic liver transplantation (OLT) can be lifesaving

143 with signs of portal hypertension undergoing orthotopic liver transplantation (OLT) carries potential

144 Early allograft rejection after orthotopic liver transplantation (OLT) currently require

145 In orthotopic liver transplantation (OLT) distinct causes o

146 is produced predominantly in the liver, and orthotopic liver transplantation (OLT) eliminates more t

147 During orthotopic liver transplantation (OLT) for acute liver f

148 Patients who undergo orthotopic liver transplantation (OLT) for Budd-Chiari s

149 ty-three HCV-positive patients who underwent orthotopic liver transplantation (OLT) for end-stage liv

150 During orthotopic liver transplantation (OLT) for fulminant hep

151 f HCV recurrence during the first year after orthotopic liver transplantation (OLT) for HCV-related c

152 Although orthotopic liver transplantation (OLT) frequently result

153 We report the results of orthotopic liver transplantation (OLT) from 33 such dono

154 In 13 patients orthotopic liver transplantation (OLT) had to be perform

155 Orthotopic liver transplantation (OLT) has been associat

156 The success of orthotopic liver transplantation (OLT) has been limited

157 ber of lesions that predict recurrence after orthotopic liver transplantation (OLT) has not been clea

158 ting diabetes mellitus (DM) on outcome after orthotopic liver transplantation (OLT) has not been well

159 e reported that minority patients undergoing orthotopic liver transplantation (OLT) have poorer survi

160 y and mortality in obese patients undergoing orthotopic liver transplantation (OLT) have produced con

161 on 2-5 cm or two to three lesions <3 cm) for orthotopic liver transplantation (OLT) in 30 patients as

162 d orthotopic heart transplantation (OHT) and orthotopic liver transplantation (OLT) in achieving long

163 ver disease (ALD) is a common indication for orthotopic liver transplantation (OLT) in adults.

164 successfully used as bridging therapy before orthotopic liver transplantation (OLT) in efforts to del

165 ransplant centers may be hesitant to perform orthotopic liver transplantation (OLT) in patients with

166 infection is the most common indication for orthotopic liver transplantation (OLT) in the United Sta

167 The most frequent reason for orthotopic liver transplantation (OLT) in the United Sta

168 ve previously shown that patients listed for orthotopic liver transplantation (OLT) in United Network

169 While orthotopic liver transplantation (OLT) is a durable life

170 s clearance of hepatitis C virus (HCV) after orthotopic liver transplantation (OLT) is a rare occurre

171 Thrombocytopenia after orthotopic liver transplantation (OLT) is a well recogni

172 Poor linear growth after pediatric orthotopic liver transplantation (OLT) is a well-describ

173 Orthotopic liver transplantation (OLT) is an effective t

174 Orthotopic liver transplantation (OLT) is an effective t

175 Orthotopic liver transplantation (OLT) is frequently com

176 The impact of ethnicity on outcomes after orthotopic liver transplantation (OLT) is unclear.

177 Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is universal, oft

178 profile of chronic anemia in children after orthotopic liver transplantation (OLT) is unknown.

179 Orthotopic liver transplantation (OLT) is, at present, t

180 recruitment and activation in rat syngeneic orthotopic liver transplantation (OLT) model.

181 Cavaplasty orthotopic liver transplantation (OLT) offers advantages

182 und (DUS) arterial abnormalities (DAA) after orthotopic liver transplantation (OLT) often represent a

183 Five months post-orthotopic liver transplantation (OLT) one of the patien

184 ine level 2.5 mg/dL or higher at the time of orthotopic liver transplantation (OLT) or who received d

185 osis and is a strong prognostic predictor of orthotopic liver transplantation (OLT) outcome.

186 context of liver failure negatively impacts orthotopic liver transplantation (OLT) outcomes.

187 PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35)

188 With early posttransplant bone loss, orthotopic liver transplantation (OLT) recipients experi

189 of late graft loss and long-term outcome in orthotopic liver transplantation (OLT) recipients.

190 njury and metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive.

191 Orthotopic liver transplantation (OLT) requires cold isc

192 Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly acc

193 transplantation effectively denies access to orthotopic liver transplantation (OLT) to another candid

194 Orthotopic liver transplantation (OLT) treats the severe

195 1989 to December 1992, 834 adults underwent orthotopic liver transplantation (OLT) using tacrolimus

196 on on graft and patient survival rates after orthotopic liver transplantation (OLT) using the United

197 Orthotopic liver transplantation (OLT) was performed in

198 Orthotopic liver transplantation (OLT) was performed in

199 y, the records of 325 patients who underwent orthotopic liver transplantation (OLT) were reviewed.

200 We prospectively studied children after orthotopic liver transplantation (OLT) with hemoglobin l

201 t antithymocyte globulin (RATG) induction in orthotopic liver transplantation (OLT) with tacrolimus m

202 th hepatocellular carcinoma (HCC) listed for orthotopic liver transplantation (OLT) within and outsid

203 failure is the single leading indication for orthotopic liver transplantation (OLT) worldwide.

204 d by ex vivo reperfusion or transplantation (orthotopic liver transplantation (OLT)) using an anti-PS

205 pSmad 2/3 was seen as early as 24 days after orthotopic liver transplantation (OLT), although no othe

206 C virus (HCV) infection usually recurs after orthotopic liver transplantation (OLT), and most patient

207 on portal hypertension and implications for orthotopic liver transplantation (OLT), however, require

208 During orthotopic liver transplantation (OLT), it is standard p

209 In the context of orthotopic liver transplantation (OLT), renal dysfunctio

210 recovered spontaneously; 10 (50%) underwent orthotopic liver transplantation (OLT), while six (30%)

211 WHVP-IVC (HVPG-IVC), better correlates with orthotopic liver transplantation (OLT)-free survival.

212 rative graft function in patients undergoing orthotopic liver transplantation (OLT).

213 has been associated with poor outcomes after orthotopic liver transplantation (OLT).

214 maximum utilization of donor allografts for orthotopic liver transplantation (OLT).

215 (HCV) is now the most common indication for orthotopic liver transplantation (OLT).

216 tant causes of morbidity and mortality after orthotopic liver transplantation (OLT).

217 ve treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT).

218 dies have evaluated long-term outcomes after orthotopic liver transplantation (OLT).

219 uncommon but often fatal complication after orthotopic liver transplantation (OLT).

220 ents with chronic liver disease patients for orthotopic liver transplantation (OLT).

221 eived re-OLT more than 90 days after primary orthotopic liver transplantation (OLT).

222 key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT).

223 correlate with the course of infection after orthotopic liver transplantation (OLT).

224 or rabbit antithymocyte globulin (RATG) for orthotopic liver transplantation (OLT).

225 n her sibling, whose liver had been used for orthotopic liver transplantation (OLT).

226 d risk of ischemic heart disease (IHD) after orthotopic liver transplantation (OLT).

227 itively with liver disease progression after orthotopic liver transplantation (OLT).

228 ing FK506 as a part of immunosuppression for orthotopic liver transplantation (OLT).

229 injury in many deleterious complications of orthotopic liver transplantation (OLT).

230 ailure in children, frequently necessitating orthotopic liver transplantation (OLT).

231 to the ICU are often evaluated for possible orthotopic liver transplantation (OLT).

232 rus-(HBV) infected patients before and after orthotopic liver transplantation (OLT).

233 the morbidity and mortality associated with orthotopic liver transplantation (OLT).

234 r rejection and graft/patient survival after orthotopic liver transplantation (OLT).

235 hepatitis occurring de novo after pediatric orthotopic liver transplantation (OLT).

236 bleeding or treat intractable ascites before orthotopic liver transplantation (OLT).

237 disease (ESLD) and that it increases during orthotopic liver transplantation (OLT).

238 ant murine model of hepatic cold storage and orthotopic liver transplantation (OLT).

239 Solid cancers are a major adverse outcome of orthotopic liver transplantation (OLT).

240 and liver injury in pediatric patients after orthotopic liver transplantation (OLT).

241 rahepatic portosystemic shunting (TIPS), and orthotopic liver transplantation (OLT).

242 major cause of morbidity and mortality after orthotopic liver transplantation (OLT).

243 ) remains an important challenge in clinical orthotopic liver transplantation (OLT).

244 tended hepatic cold preservation followed by orthotopic liver transplantation (OLT).

245 djuvant chemoradiation treatment followed by orthotopic liver transplantation (OLT).

246 patients with end-stage renal disease after orthotopic liver transplantation (OLT).

247 brain injury (BI) in ALF patients undergoing orthotopic liver transplantation (OLT).

248 injury remains a major challenge in clinical orthotopic liver transplantation (OLT).

249 en to be a potent immunosuppressive agent in orthotopic liver transplantation (OLT).

250 h hepatocellular carcinoma (HCC) who receive orthotopic liver transplantation (OLT).

251 cute pulmonary and cardiac failure following orthotopic liver transplantation (OLT).

252 survival in patients with cirrhosis awaiting orthotopic liver transplantation (OLT).

253 enase-1 (HO-1)-inducing regimens in clinical orthotopic liver transplantation (OLT).

254 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver

255 One method for increasing the donor pool for orthotopic liver transplantations (OLTs) is to use uncon

256 end-stage liver disease who were undergoing orthotopic liver transplantation (OLTX) after the availa

257 major cause of morbidity and mortality after orthotopic liver transplantation (OLTX) and is predomina

258 Fourteen patients underwent orthotopic liver transplantation (OLTx) for PLD between

259 Their use in orthotopic liver transplantation (OLTX) has dramatically

260 Neurological complications after orthotopic liver transplantation (OLTX) have remained a

261 Orthotopic liver transplantation (OLTX) is the treatment

262 Acute renal failure developing after orthotopic liver transplantation (OLTx) requiring renal

263 m creatinine (sCr) <1.0 mg/dL (n=143) before orthotopic liver transplantation (OLTX) were included in

264 patitis (AIH), as an original indication for orthotopic liver transplantation (OLTX), predisposes to

265 ated cirrhosis is the leading indication for orthotopic liver transplantation (OLTx).

266 ate, the risk of brainstem herniation unless orthotopic liver transplantation or spontaneous liver re

267 performed at the last MR examination before orthotopic liver transplantation or surgical resection.

268 cept further alcoholic rehabilitation before orthotopic liver transplantation, P=0.01.

269 tochemistry in allograft biopsy specimens of orthotopic liver transplantation patients with recurrent

270 tion patients, and 14.26 dollars for the non-orthotopic liver transplantation patients).

271 95 dollars in charges (51.03 dollars for the orthotopic liver transplantation patients, and 14.26 dol

272 Four underwent repeat piggyback orthotopic liver transplantation prior to intervention.

273 failure; c) patients immediately status post-orthotopic liver transplantation receiving a steroid-fre

274 Orthotopic liver transplantation remains the only effect

275 Orthotopic liver transplantation remains the only effect

276 Orthotopic liver transplantation remains the only establ

277 ations after OLT, the Cardiovascular Risk in Orthotopic Liver Transplantation risk score, among a coh

278 Sixteen months after orthotopic liver transplantation, she is HBV DNA seroneg

279 at dependency on RRT in the first week after orthotopic liver transplantation stems almost entirely f

280 Orthotopic liver transplantation substantially reduces t

281 After orthotopic liver transplantation, survival, serum transa

282 ation has been proposed as an alternative to orthotopic liver transplantation to treat metabolic live

283 rgical choices in complex procedures such as orthotopic liver transplantation trigger a chain of even

284 A prospective trial in orthotopic liver transplantation using Mycophenolate Mof

285 ence of CMV DNA for the first 12 weeks after orthotopic liver transplantation using the Murex hybrid

286 Orthotopic liver transplantation, using whole or partial

287 We first introduced the orthotopic liver transplantation utilizing cavaplasty te

288 The mean interval between chemotherapy and orthotopic liver transplantation was 111 days (range, 3-

289 col combining neoadjuvant chemoradiation and orthotopic liver transplantation was first used in patie

290 Orthotopic liver transplantation was performed between p

291 the efficacy of hepatocyte transplantation, orthotopic liver transplantation was performed successfu

292 Orthotopic liver transplantation was performed using ste

293 Orthotopic liver transplantation was performed with 18-h

294 Using experimental orthotopic liver transplantation, we showed that the eff

295 of Ireland, 606 patients undergoing a first orthotopic liver transplantation were randomly assigned

296 asures of disease severity/progression, like orthotopic liver transplantation, when genetic analyses

297 ho had a hepatic artery pseudoaneurysm after orthotopic liver transplantation, which was successfully

298 of CD39 on liver mDCs in vivo, we performed orthotopic liver transplantation with extended cold pres

299 The standard technique of orthotopic liver transplantation with venovenous bypass

300 expression/activation of MMP-9 in steatotic orthotopic liver transplantations without significantly